Eli Lilly's experimental weight loss drug shed 21% of body weight in diabetes trial
Eli Lilly has developed new weight loss drugs for people with Type 2 diabetes. In late-stage trials, one drug called retatrutide helped patients lose up to 60 pounds, or about 23% of their body weight. The company also tested a combination drug that performed even better than tirzepatide alone in earlier trials. The results were published in medical journals this week.
7 across the spectrum · tap a section to jump
The story so far
2 developments- Sep 29People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug
- Sep 30Eli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster
Who covered each development
Left
3 viewpointsEli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster
Eli Lilly's experimental weight loss drug shed 21% of body weight in diabetes trial
People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug
Center
4 viewpointsNew investigational drug delivers up to 23.3% weight loss in people with obesity and diabetes
STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
People with Type 2 diabetes lost up to 60 pounds on Lilly's latest weight loss drug
Right
0 viewpointsNo Right coverage yet.
A blind spot on this side of the story.